



## **PrescribeIT Baseline Study**

**Dr. Neil McEvoy**

**March 18, 2019**

Contents	2
<b>1 Background to the Study</b>	<b>3</b>
1.1 Overall purpose . . . . .	3
1.2 Summary of Phase 1 Workflow . . . . .	3
1.3 Goals of Phase 2 Baseline . . . . .	3
1.4 Design of Phase 2 Baseline . . . . .	3
<b>2 Phase 2 Baseline Findings</b>	<b>3</b>
2.1 Selected sites . . . . .	4
2.2 Prescribers . . . . .	4
2.3 Dispensers . . . . .	4
2.4 Salient findings . . . . .	4
<b>3 Anticipating Phase 3 Increments</b>	<b>4</b>
3.1 Survey extension . . . . .	4
3.2 Potential findings . . . . .	4
<b>4 Reference Materials</b>	<b>4</b>



## 1 Background to the Study

The baseline study reported here is the second phase of a three phase project intended to gather evidence of the benefits of PrescribIT in prescribing and dispensing medications.

### 1.1 Overall purpose

The overall purpose of the project is to gather evidence of the benefits of PrescribIT.

### 1.2 Summary of Phase 1 Workflow

The first phase examined workflow at selected physician offices and dispenser outlets. The study identified patterns of flow, and exposed key processes at which changes due to PrescribIT might contribute improvements.

### 1.3 Goals of Phase 2 Baseline

The goal of the second phase is to establish baseline indicators close to the introduction of PrescribIT as measures against which future changes could be compared.

### 1.4 Design of Phase 2 Baseline

The phase uses indicator sets developed in light of the findings of the initial workflow phase. Each is tailored to the specifics of dispensers and prescribers respectively.

The indicators were assembled as a secure website designed for secure yet easy access.

The indicators are shown in the following tables

## 2 Phase 2 Baseline Findings

The following figures illustrate the base line indicators.

Sepal.Length	Sepal.Width	Petal.Length	Petal.Width	Species
5.10	3.50	1.40	0.20	setosa
4.90	3.00	1.40	0.20	setosa
4.70	3.20	1.30	0.20	setosa
4.60	3.10	1.50	0.20	setosa
5.00	3.60	1.40	0.20	setosa
5.40	3.90	1.70	0.40	setosa
4.60	3.40	1.40	0.30	setosa
5.00	3.40	1.50	0.20	setosa
4.40	2.90	1.40	0.20	setosa
4.90	3.10	1.50	0.10	setosa
5.40	3.70	1.50	0.20	setosa
4.80	3.40	1.60	0.20	setosa
4.80	3.00	1.40	0.10	setosa
4.30	3.00	1.10	0.10	setosa
5.80	4.00	1.20	0.20	setosa
5.70	4.40	1.50	0.40	setosa
5.40	3.90	1.30	0.40	setosa
5.10	3.50	1.40	0.30	setosa
5.70	3.80	1.70	0.30	setosa
5.10	3.80	1.50	0.30	setosa

## **2.1 Selected sites**

The following sites were selected for participation by CHI Prescribers:

## **2.2 Prescribers**

## **2.3 Dispensers**

## **2.4 Salient findings**

## **3 Anticipating Phase 3 Increments**

---

### **3.1 Survey extension**

### **3.2 Potential findings**

## **4 Reference Materials**

---